41
Participants
Start Date
October 31, 2014
Primary Completion Date
May 9, 2018
Study Completion Date
July 23, 2018
Omaveloxolone Capsules (2.5 mg/capsule)
Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
Ipilimumab (3 mg/kg)
Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg
Nivolumab (240 mg)
Sterile solution containing nivolumab to be delivered intravenously at 240 mg
Omaveloxolone Capsules (10 mg/capsule)
Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
Omaveloxolone Capsules (50 mg/capsule)
Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
Christiana Hospital Helen F. Graham Cancer Center, Newark
Goergetown-Lombardi Comprehensive Cancer Center, Washington D.C.
Duke Cancer Institute, Durham
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Southern Cancer Center, Mobile
Highlands Oncology Group, Fayetteville
MD Anderson Cancer Center, Houston
University of Colorado Cancer Center, Anschutz Cancer Pavilion, Aurora
Dana Farber Cancer Institute, Boston
Atlantic Melanoma Center, Morristown
Lead Sponsor
Biogen
INDUSTRY